Michelle Mierzwa is an Oncology physician affiliated with University of Michigan. OpenAlex indexes 341 publications with 2,843 citations (h-index 29); ClinicalTrials.gov lists 9 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Drive
B2 Floor University Hospital Rm C490
Ann Arbor, MI 481095010
Telephone
734-936-4300Registry record last updated 23 Jun 2015.
Clinical trials
- Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer
Sponsor: University of Michigan Rogel Cancer Center
- A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
Sponsor: University of Michigan Rogel Cancer Center
- Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
Sponsor: University of Michigan Rogel Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Siemens Medical Solutions USA, Inc.Program year20253 payments
- Siemens Medical Solutions USA, Inc.Program year20234 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
65.2%Antiarrhythmic65.2%Lidocaine Hcl Viscous100%Part D≥21 patientsSensory organs
34.8%Corticosteroid34.8%Dexamethasone100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Quality and Safety Considerations for Adaptive Radiation Therapy: An ASTRO White Paper
International Journal of Radiation Oncology*Biology*Physics
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Moshe Talpaz, MD
University of Michigan
William Herman, MD
University of Michigan
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”